碩世生物(688399.SH)：擬以4000萬元投資宏元生物 其致力於開發新一代腫瘤無創早篩/早診產品
格隆匯4月18日丨碩世生物(688399.SH)公佈，為完善公司業務佈局，充分整合利用各方優勢資源，加強公司在分子診斷領域的多元佈局，公司擬以自有資金投資蘇州宏元生物科技有限公司(“宏元生物”或者“投資標的”)，公司已於2022年4月18日就本次增資事宜與宏元生物及其原股東簽署《增資協議》。
宏元生物擬將註冊資本由122.9422萬元增加至135.2364萬元，新增加註冊資本將由公司全額認繳。根據各方認可宏元生物本次投前估值4億元人民幣，公司此次以總計人民幣4000萬元的對價溢價認繳上述新增註冊資本。此次增次完成後，公司持有宏元生物9.0909%的股權。公司投資額與新增註冊資本之間的差額計入宏元生物資本公積。
公吿顯示，宏元生物創立於2018年，致力於開發新一代腫瘤無創早篩/早診產品。目前宏元生物主營業務為無創尿液DNA分子診斷，屬於IVD領域發展較快的細分領域，特別是NGS(第二代測序技術)近幾年發展迅速，在腫瘤基因檢測應用前景廣闊。
宏元生物擁有超靈敏染色體畸變檢測技術平台，該技術憑藉獨特的算法技術，將高通量測序(NGS)和大數據挖掘為核心的信息技術緊密結合，能夠挖掘到與腫瘤有關的少量染色體畸變。
通過該技術平台孵化的拳頭產品“尿路上皮癌染色體異常檢測試劑盒(UroCADⓇ) ”，在2021年通過國家《創新醫療器械特別審查程序》。該創新審查是中國體外診斷行業創新認證最高標準，通過該特別審查程序，宏元生物 UroCAD有望成為業內首個取得註冊證的腫瘤早診/篩查NGS產品，該產品還獲得美國臨牀腫瘤學會(ASCO)和《中國泌尿外科和男科疾病診斷治療指南》引用和認可。與此同時，宏元生物也正在進行其他高發癌症的早篩早診產品的開發，包括肺癌、肝癌、膽道癌症、胰腺癌、 乳腺癌、子宮內膜癌、前列腺癌等，涵蓋癌症的輔助診斷、風險預測、用藥指導、復發監測等領域。
此次增資是公司為完善業務佈局而進行，與公司目前戰略布局相符，與主營業務具有協同效應，立足主營業務的同時加強其在分子診斷領域多元佈局拓展和嘗試，尤其是腫瘤早篩早診領域，積極開發新的技術領域，拓展行業機會，為進一步發展壯大奠定基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
